Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 18/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5362616 | 0.81 | BDKRB1 (0.44) | BDKRB1 | |
| Ammonia Solution, Strong SCHEMBL27624658 | 0.74 | BDKRB1 (0.45) | BDKRB1NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL13846198 | 0.73 | NPC1 (0.48) | BDKRB1NPC1NFKB1RAB9ANFKB2 | |
| Hydrochloric Acid SCHEMBL6183477 | 0.71 | BDKRB1 (0.45) | BDKRB1NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL5360427 | 0.71 | BDKRB1 (0.48) | BDKRB1NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL5360555 | 0.71 | BDKRB1 (0.47) | BDKRB1 | |
| SCHEMBL5367209 | 0.70 | BDKRB1 (0.43) | BDKRB1 | |
| Hydrochloric Acid SCHEMBL6185533 | 0.69 | BDKRB1 (0.56) | BDKRB1NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL5374210 | 0.67 | NPC1 (0.43) | BDKRB1NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL13363264 | 0.67 | NPC1 (0.43) | BDKRB1NPC1NFKB1RAB9ANFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163951-B2 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | MERCK & CO., INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20050288305-A1 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | MERCK SHARP & DOHME CORP. | 2005-12-29 | — | — | US | disclosed |
| EP-1545538-A2 | N-BIARYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | Merck & Co., Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| WO-2004019868-A2 | N-BIARYLMETHYL AMINOCYCLOALKANECARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288305-A1 | N-biarylmethyl aminocycloalkanecarboxamide derivatives | BDKRB1, BDKRB2, LTB4R2 | BDKRB1 1/4885NPC1 1679/4885NFKB1 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.